Neo on the Weekly Looking at #neo as it previously broke the rising wedge with a weekly triple top. if monthly support brakes in red we will have a continuation to the downside. floor levels marked.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.62 USD
−87.97 M USD
591.64 M USD
126.77 M
About NeoGenomics, Inc.
Sector
Industry
CEO
Christopher Michael Smith
Website
Headquarters
Fort Myers
Founded
1998
FIGI
BBG000BKH263
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
$NEO Setting UpNASDAQ:NEO tight at its 50 MA after quick shakeout below that level.
Breaking downtrend line (red dotted line) and holding.
I bit light on the $ avg. volume but looks good.
Now or never for this one.
Neo founder: Decentralized innovation is not a race, blockchain Coin World reported that Neo is a smart contract platform established in 2014. Da Hongfei, the founder of Neo, said that the protocol regards itself as a pragmatic participant and is committed to promoting a platform that relies on blockchain technology to meet its transaction needs. world. He added
NEOGENOMICS Stock Chart Fibonacci Analysis 042223Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 16.2/61.80%
NEO7$ support as long as it holds could be setting up as a double bottom. Still a bit early and this floor could fall out, howverr if we can see buyers control the. We could see a push up to the neckline of 12.95 area. Watching this tomrorow could be setting up!
NeoGenomics Inc 🧙NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogen
NEO Good time to enterMIssed this one one for what seemed like every day for 2 months as it never slowed down. Time for a good entry in LT account. Should bounce from these levels.
$NEO Cypher pattern Bounce spot $NEO, CEO stepped down and market pulled back, still think this bounces back, let's see
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NEO is featured.
Frequently Asked Questions
The current price of NEO is 15.77 USD — it has decreased by −0.32% in the past 24 hours. Watch NeoGenomics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeoGenomics, Inc. stocks are traded under the ticker NEO.
NEO stock has risen by 15.11% compared to the previous week, the month change is a 17.77% rise, over the last year NeoGenomics, Inc. has showed a −0.38% decrease.
We've gathered analysts' opinions on NeoGenomics, Inc. future price: according to them, NEO price has a max estimate of 30.00 USD and a min estimate of 16.00 USD. Watch NEO chart and read a more detailed NeoGenomics, Inc. stock forecast: see what analysts think of NeoGenomics, Inc. and suggest that you do with its stocks.
NEO stock is 3.14% volatile and has beta coefficient of 1.09. Track NeoGenomics, Inc. stock price on the chart and check out the list of the most volatile stocks — is NeoGenomics, Inc. there?
Today NeoGenomics, Inc. has the market capitalization of 2.02 B, it has increased by 3.37% over the last week.
Yes, you can track NeoGenomics, Inc. financials in yearly and quarterly reports right on TradingView.
NeoGenomics, Inc. is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
NEO earnings for the last quarter are 0.05 USD per share, whereas the estimation was 0.01 USD resulting in a 305.81% surprise. The estimated earnings for the next quarter are 0.03 USD per share. See more details about NeoGenomics, Inc. earnings.
NeoGenomics, Inc. revenue for the last quarter amounts to 167.82 M USD, despite the estimated figure of 167.00 M USD. In the next quarter, revenue is expected to reach 172.99 M USD.
NEO net income for the last quarter is −17.70 M USD, while the quarter before that showed −18.64 M USD of net income which accounts for 5.06% change. Track more NeoGenomics, Inc. financial stats to get the full picture.
No, NEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 2.10 K employees. See our rating of the largest employees — is NeoGenomics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NeoGenomics, Inc. EBITDA is −13.40 M USD, and current EBITDA margin is −4.07%. See more stats in NeoGenomics, Inc. financial statements.
Like other stocks, NEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeoGenomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeoGenomics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeoGenomics, Inc. stock shows the buy signal. See more of NeoGenomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.